Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CATIE Suggests Zyprexa Useful As Initial Schizophrenia Treatment – NEJM

Executive Summary

Results of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study suggest Lilly's Zyprexa may be well suited as initial therapy in the treatment of schizophrenia, according to an editorial accompanying the study

Related Content

CER Credibility Lies In Methodology For Studies, Physician Tells BIO
FDA's U-Turn On Fanapt: Comparative Assessments Must Have Clinical Meaning
Lilly To Settle Additional Zyprexa Liability Cases, Will Pay Up To $500 Million
CATIE Cost-Effectiveness Study Favors Perphenazine Over Atypicals
Older Antipsychotic Tops New Branded Drugs In Consumer Reports Review
Antipsychotic Trials Biased Towards Sponsor’s Drug, Study Suggests
AHRQ Comparative Effectiveness Reviews Will Expand Beyond Medicare
Antipsychotic Risk Examined In NEJM; Did FDA Judge Atypicals Unfairly?
Antipsychotic Mortality Risk Analysis By Independent Group Needed
Cymbalta “Mood” And “Pain” Claims May Include Fibromyalgia And Anxiety





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts